According to the latest report published by Credence Research, Inc. Next Generation Sequencing Market  (Technology Type Whole Genome Sequencing, Targeted Resequencing, RNA Sequencing, Whole Exome Sequencing, and De Novo Sequencing); (Application Oncology, Genetic Screening, Infectious Diseases, Drug and Biomarker Discovery, Agriculture & Animal Research, Idiopathic Diseases and others): Market Growth, Future Prospects and Competitive Analysis, 2016-2024 the market was valued at USD 2.6 Bn in 2015, and is expected to reach USD 20.6 Bn by 2025, expanding at a CAGR of 21.5% from 2016 to 2025.

Browse the full report Next Generation Sequencing Market: Market Growth, Future Prospects and Competitive Analysis, 2016-2025 report at http://www.credenceresearch.com/report/next-generation-sequencing-market

Market Insights                                                  

Next generation sequencing is a high-throughput sequencing that enables sequencing and assembling of number of short DNA reads at a small period of time and with a better accuracy. The introduction of next generation sequencing technologies has ensured massive changes in the sequencing process by providing better output, higher speed, flexibility and reduced sequencing cost over thousand folds. Technologically, the approaches for any next generation sequencing procedure can be categorized into whole genome sequencing, targeted resequencing, Rna sequencing, whole exome sequencing and de novo sequencing. With the advancement in technology and development of high throughput sequencing platforms such as HiSeq and MiSeq, it has become increasingly efficient to sequence larger number of base pairs in single cycle reads. Targeted resquencing held the largest share in the global next generation sequencing market due to its accuracy, and its rising preferences in the research and development. De novo sequencing is anticipated to grow at the fastest rate during the forecast period due to its faster, more accurate characterization of any species compared to traditional methods.

Next-generation sequencing (NGS) technologies have progressive advantages in terms of cost-effectiveness, unprecedented sequencing speed, high resolution and accuracy in genomic analyses. Technological developments in the next generation sequencing market are expected to enable researchers to generate phase resolved HLA sequences in single read cycles and provide insight into the lesser accessible regions of HLA genes. Furthermore, the development of prenatal genome sequencing for analysis of genetic anomalies and diseases is also expected to witness enhanced demand, thus driving the genetic screening market. Growing incidences of cancer and infectious diseases, and increasing use of next generation sequencing to develop biopharmaceuticals and drugs for their cure are further expected to drive demand for next generation sequencing.

Geographically, North America was observed as the largest revenue generating market for next generation sequencing market, where the U.S. held the largest market share. The major factors driving the market are technological advancements in the field of life sciences, availability of commercial solutions for next generation sequencing data analysis, and presence of key players in the region. Moreover, extended support from the government institution for genomic research for drug discovery and genetic screening is also driving the market for next generation sequencing in North America and Europe. Asia-Pacific is expected to grow at the fastest rate with throughout the forecast period owing to growing medical awareness in the regional population, increasing investment for development of healthcare and rising oncology and infectious disease research in the region.

Market Competition Assessment:

The next generation sequencing market currently possesses numerous companies having their products marketed, however, Illumina, Inc. dominates the market wholly. Most of the companies are located in the North America and others developed regions. The companies have untapped opportunities in the developing regions of Asia Pacific and Latin America. Companies are coming up with various products in the developed nations due to high acceptance and accessibilities of these products. The companies include, ThermoFisher Scientific, Pacific Biosciences of California, F.Hoffman-La Roche AG Qiagen, BGI and Others.

Key Market Movements:

• Continuous introduction of new products and high level of accuracy offered by the products have accelerated the demand of next generation sequencers
• Extended clinical application of the next generation sequencing technologies in the field of various diseases and drug discovery driving the market

Browse the full report Next Generation Sequencing Market: Market Growth, Future Prospects and Competitive Analysis, 2016-2025 report at http://www.credenceresearch.com/report/next-generation-sequencing-market

 Latest Reports:

Aloe Vera Extracts Market: http://www.credenceresearch.com/press/global-aloe-vera-extracts-market

The high demand for low-cost sequencing has driven the development of high-throughput sequencing, which also goes by the term next generation sequencing (NGS). Thousands or millions of sequences are concurrently produced in a single next-generation sequencing process. Next generation sequencing has become a commodity. With the commercialization of various affordable desktop sequencers, NGS has become within the reach of traditional wet-lab biologists. As seen in recent years, genome-wide scale computational analysis is increasingly being used as a backbone to foster novel discovery in biomedical research. However, as the quantities of sequence data increase exponentially, the analysis bottle-neck is yet to be solved.

The current sources for NGS informatics are extremely fragmented. A novice could read review articles in various journals, follow discussion threads on forums such as Biostar[1] or SEQanswers [2], or sign up for courses organized by various institutes. Finding a centralized synthesis is much more difficult. Books are available, but the development of the field is so fast that book chapters risk being obsoleted by the time they are even printed. Moreover, cost for a handful of authors to continually update their text would presumably take up a lot of their schedule.

Drawing from the obvious goodwill and community spirit displayed on discussion forums, and exploiting the collaborative tools made available by the Wikimedia foundation, we propose to initiate the editing of a collaborative WikiBook on NGS. Our plan is to collect a sufficient amount of text that people will be incentivized to contribute to it, essentially providing the same information as a forum but in a tidier form. Ultimately, our goal is to create a collective lab book that explains the key concepts and describes best practices in NGS.

Source : Wikipedia

What is Next Generation Sequencing?

Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionised genomic research. Using NGS an entire human genome can be sequenced within a single day. In contrast, the previous Sanger sequencing technology, used to decipher the human genome, required over a decade to deliver the final draft. Although in genome research NGS has mostly superseded conventional Sanger sequencing, it has not yet translated into routine clinical practice. The aim of this article is to review the potential applications of NGS in paediatrics.

There are a number of different NGS platforms using different sequencing technologies, a detailed discussion of which is beyond the scope of this article. However, all NGS platforms perform sequencing of millions of small fragments of DNA in parallel. Bioinformatics analyses are used to piece together these fragments by mapping the individual reads to the human reference genome. Each of the three billion bases in the human genome is sequenced multiple times, providing high depth to deliver accurate data and an insight into unexpected DNA variation (figure 1). NGS can be used to sequence entire genomes or constrained to specific areas of interest, including all 22000 coding genes (a whole exome) or small numbers of individual genes.

[Ref: ncbi.nlm.nih.gov]

About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com